Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Thursday

Key Points

• Corvus Pharmaceuticals is set to announce its Q2 2025 earnings on August 5th, with analysts expecting a loss of ($0.13) per share.
• Following a recent sale of shares by a director, the company's stock has experienced a 1.3% decline, opening at $4.65.
• Corvus Pharmaceuticals has a consensus rating of "Moderate Buy" based on recent analyst reviews, with target prices ranging up to $17.00.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Corvus Pharmaceuticals Price Performance

NASDAQ:CRVS traded down $0.07 during mid-day trading on Friday, reaching $4.10. The stock had a trading volume of 604,705 shares, compared to its average volume of 436,656. The stock's 50 day simple moving average is $4.11 and its two-hundred day simple moving average is $4.09. Corvus Pharmaceuticals has a 1-year low of $2.54 and a 1-year high of $10.00. The company has a market capitalization of $279.50 million, a price-to-earnings ratio of -4.18 and a beta of 0.42.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CRVS shares. Oppenheimer reaffirmed an "outperform" rating and set a $17.00 price target (up previously from $15.00) on shares of Corvus Pharmaceuticals in a report on Friday, May 9th. Mizuho set a $11.00 price target on Corvus Pharmaceuticals and gave the company an "outperform" rating in a report on Tuesday, May 20th. Finally, Wall Street Zen cut Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, May 20th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $15.00.

Insider Activity

In related news, Director Peter A. Thompson sold 1,176,332 shares of Corvus Pharmaceuticals stock in a transaction on Friday, June 27th. The shares were sold at an average price of $4.16, for a total value of $4,893,541.12. Following the completion of the sale, the director owned 7,165,006 shares of the company's stock, valued at approximately $29,806,424.96. The trade was a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 28.50% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.